Table 1. Clinicopathological features of tumour specimens in relation to KRAS, NRAS and BRAF gene mutation status.
| KRAS mut n (%) | NRAS mut n (%) | BRAF mut n (%) | RAS/BRAF WT n (%) | Total n (%) | |
|---|---|---|---|---|---|
|
Sex | |||||
| F | 52 (48.1) | 6 (5.6) | 10 (9.3)a | 40 (37.0) | 108 (45.0) |
| M | 61 (46.2) | 8 (6.1) | 2 (1.5) | 61 (46.2) | 132 (55.0) |
| Sub total | 113 (47.1) | 14 (5.8) | 12 (5.0) | 101 (42.1) | 240 (100) |
|
Age (years) | |||||
| Median | 64 | 68 | 65,5 | 63,5 | — |
| Range | 34–84 | 40–87 | 51–73 | 22–92 | — |
| Sub total | 101 (47.2) | 13 (6.1) | 10 (4.7) | 90 (42.0) | 214 (100) |
|
G | |||||
| 1–2 | 57 (48.7) | 5 (4.3) | 1 (0.9) | 54 (27.3) | 117 (71.8) |
| 3–4 | 21 (45.6) | 4 (8.7) | 5 (10.9)a | 16 (34.8) | 46 (28.2) |
| Sub total | 78 (47.8) | 9 (5.5) | 6 (3.7) | 70 (42.9) | 163 (100) |
|
pT | |||||
| 1–2 | 5 (55.5) | 1 (11.1) | 0 (0) | 3 (0) | 9 (5.5) |
| 3–4 | 73 (47.4) | 8 (5.2) | 6 (3.4) | 67 (43.5) | 154 (94.5) |
| Sub total | 78 (47.8) | 9 (5.5) | 6 (3.7) | 70 (42.9) | 163 (100) |
|
pN | |||||
| 0 | 19 (46.3) | 3 (7.3) | 2 (4.9) | 17 (41.5) | 41 (25.6) |
| 1 | 36 (56.3) | 3 (4.7) | 0 (0) | 25 (39.1) | 64 (40.0) |
| 2 | 21 (38.2) | 2 (3.6) | 4 (7.3) | 28 (50.9) | 55 (34.4) |
| Sub total | 76 (47.5) | 8 (5.0) | 6 (3.8) | 70 (43.7) | 160 (100) |
|
Vascular and/or perineural invasion | |||||
| Yes | 52 (44.8) | 6 (5.2) | 4 (3.4) | 54 (41.7) | 116 (78.4) |
| No | 17 (53.1) | 2 (6.3) | 1 (3.1) | 12 (37.5) | 32 (21.6) |
Abbreviations: mut=mutated; WT=wild-type; F=female; M=male.
a
BRAF mutations are significantly more prevalent in female patients (F) and G3-G4 tumours rather than in males (M) and G1-G2 tumours (P=0.013).